Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

NCT04891237 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhinitis, Allergic
Rhinoconjunctivitis
Asthma, Allergic

Interventions

BIOLOGICAL: 10,000 MG01 + 10,000 T517
BIOLOGICAL: 30,000 MG01 + 10,000 T517
OTHER: Placebo

Sponsor

Inmunotek S.L.